SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for ORTHOPEDIATRICS CORP (KIDS) (CIK 0001425450) (KIDS) — Mar 23, 2020

ORTHOPEDIATRICS CORP (KIDS) (CIK 0001425450)
Date: March 23, 2020 · CIK: 0001425450 · Accession: 0000000000-20-002522

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-237177

Date
March 23, 2020
Author
Courtney Lindsay
Form
UPLOAD
Company
ORTHOPEDIATRICS CORP (KIDS) (CIK 0001425450)

Letter

March 23, 2020 Fred Hite Chief Financial Officer OrthoPediatrics Corp. 2850 Frontier Drive Warsaw, IN 46582 Re:OrthoPediatrics Corp. Registration Statement on Form S-3 Filed March 13, 2020 File No. 333-237177 Dear Mr. Hite: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Courtney Lindsay at (202) 551-7237 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
March 23, 2020
Fred Hite
Chief Financial Officer
OrthoPediatrics Corp.
2850 Frontier Drive
Warsaw, IN 46582
Re:OrthoPediatrics Corp.
Registration Statement on Form S-3
Filed March 13, 2020
File No. 333-237177
Dear Mr. Hite:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Courtney Lindsay at (202) 551-7237 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences